187 related articles for article (PubMed ID: 16831932)
21. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
[TBL] [Abstract][Full Text] [Related]
22. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
23. Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation.
Glass DA; Karsenty G
Ann N Y Acad Sci; 2006 Apr; 1068():117-30. PubMed ID: 16831912
[TBL] [Abstract][Full Text] [Related]
24. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
25. Effects of bone cement particles on the function of pseudocapsule-derived fibroblasts.
Sun SG; Ma BA; Zhou Y; Zhang MH; Fan QY
Acta Orthop; 2006 Apr; 77(2):320-8. PubMed ID: 16752297
[TBL] [Abstract][Full Text] [Related]
26. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
Dovio A; Data V; Angeli A
J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
[TBL] [Abstract][Full Text] [Related]
27. [Effects of the osteoclast in pathogenesis of multiple myeloma].
Zhang JH; Fu JX; Zhang XH; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
[TBL] [Abstract][Full Text] [Related]
28. Revisiting the seed and soil theory of bone metastasis: new tools, same answer.
Kostenuik PJ
J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):375-6. PubMed ID: 15758267
[No Abstract] [Full Text] [Related]
29. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
Brunetti G; Colucci S; Rizzi R; Mori G; Colaianni G; Oranger A; Zallone A; Liso V; Grano M
Ann N Y Acad Sci; 2006 Apr; 1068():334-40. PubMed ID: 16831934
[TBL] [Abstract][Full Text] [Related]
30. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
Abe M; Hiura K; Wilde J; Moriyama K; Hashimoto T; Ozaki S; Wakatsuki S; Kosaka M; Kido S; Inoue D; Matsumoto T
Blood; 2002 Sep; 100(6):2195-202. PubMed ID: 12200385
[TBL] [Abstract][Full Text] [Related]
31. Role of osteoprotegerin (OPG) in cancer.
Holen I; Shipman CM
Clin Sci (Lond); 2006 Mar; 110(3):279-91. PubMed ID: 16464170
[TBL] [Abstract][Full Text] [Related]
32. Multiple myeloma.
Schneider HG; Sentry J
N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736296
[No Abstract] [Full Text] [Related]
33. Advances in the biology and treatment of myeloma bone disease.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 17):11-6. PubMed ID: 12520479
[TBL] [Abstract][Full Text] [Related]
34. Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling.
Pearse RN
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6274s-6278s. PubMed ID: 17062713
[TBL] [Abstract][Full Text] [Related]
35. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
36. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.
Lee JW; Chung HY; Ehrlich LA; Jelinek DF; Callander NS; Roodman GD; Choi SJ
Blood; 2004 Mar; 103(6):2308-15. PubMed ID: 14615378
[TBL] [Abstract][Full Text] [Related]
37. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
Tanaka S
Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
[TBL] [Abstract][Full Text] [Related]
38. RANKL signaling in bone physiology and cancer.
Dougall WC
Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
[TBL] [Abstract][Full Text] [Related]
39. [Mutual interaction between myeloma cells and bone marrow microenvironment].
Abe M
Rinsho Ketsueki; 2009 Jun; 50(6):453-60. PubMed ID: 19571504
[No Abstract] [Full Text] [Related]
40. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
